In the fifth interview of the series “Portrait of Duchenne”, our Canadian partners La Fondation La Force talked with Joanne Donovan, Chief Medical Officer at Catabasis Pharmaceuticals at the Action Duchenne International Conference 2016. 

Catabasis have been working on a potential treatment for Duchenne called edasalonexent (formerly known as CAT-1004).